SUSTAINED RELEASE OF ANTIINFECTIVES
Provided, among other things, is a method of treating or ameliorating pulmonary infection in a cystic fibrosis patient comprising pulmonary administration of an effective amount of a liposomal/complexed antiinfective to the patient, wherein the (i) administrated amount is 50% or less of the comparative free drug amount, or (ii) the dosing is once a day or less, or (iii) both.
1 . A liposomal ciprofloxacin formulation comprising ciprofloxacin encapsulated in a liposome, wherein the lipid component of the liposomes comprises cholesterol and a phosphatidylcholine, and the lipid component to ciprofloxacin weight ratio is less than 2.5:1 by weight.
2 . The liposomal ciprofloxacin formulation of claim 1 , wherein the liposomes are unilamellar.
3 . The liposomal ciprofloxacin formulation of claim 1 , wherein the phosphatidylcholine is hydrogenated soy phosphatidylcholine (HSPC).
4 . The liposomal ciprofloxacin formulation of claim 2 , wherein the phosphatidylcholine is hydrogenated soy phosphatidylcholine (HSPC).
5 . A method of treating a Pseudomonas aeruginosa infection or an infection due to P. aeruginosa in the lungs of a patient in need thereof, comprising administering to the lungs of the patient an effective amount of a liposomal ciprofloxacin formulation which comprises ciprofloxacin encapsulated in a liposome, wherein the lipid component of the liposomes comprises cholesterol and a phosphatidylcholine, and the lipid component to ciprofloxacin weight ratio is less than 2.5:1 by weight.
6 . The method of claim 5 , wherein the phosphatidylcholine is hydrogenated soy phosphatidylcholine (HSPC).
7 . The method of claim 5 , wherein the liposomes are unilamellar.
8 . The method of claim 5 , wherein the formulation is administered via inhalation.
9 . The method of claim 6 , wherein the liposomes are unilamellar.
10 . The method of claim 6 , wherein the formulation is administered via inhalation.
11 . The method of claim 7 , wherein the formulation is administered via inhalation.